Oxford Transplant Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Ann Surg. 2023 May 1;277(5):835-840. doi: 10.1097/SLA.0000000000005769. Epub 2022 Dec 5.
To report our experience with the combination of radical surgical excision and intestinal transplantation in patients with recurrent pseudomyxoma peritonei (PMP) not amenable to further cytoreductive surgery (CRS).
CRS and heated intraoperative peritoneal chemotherapy are effective treatments for many patients with PMP. In patients with extensive small bowel involvement or nonresectable recurrence, disease progression results in small bowel obstruction, nutritional failure, and fistulation, with resulting abdominal wall failure.
Between 2013 and 2022, patients with PMP who had a nutritional failure and were not suitable for further CRS underwent radical debulking and intestinal transplantation at our centre.
Fifteen patients underwent radical exenteration of affected intra-abdominal organs and transplantation adapted according to the individual case. Eight patients had isolated small bowel transplantation and 7 patients underwent modified multivisceral transplantation. In addition, in 7 patients with significant abdominal wall tumor involvement, a full-thickness vascularized abdominal wall transplant was performed. Two of the 15 patients died within 90 days due to surgically related complications. Actuarial 1-year and 5-year patient survivals were 79% and 55%, respectively. The majority of the patients had significant improvement in quality of life after transplantation. Progression/recurrence of disease was detected in 91% of patients followed up for more than 6 months.
Intestinal/multivisceral transplantation enables a more radical approach to the management of PMP than can be achieved with conventional surgical methods and is suitable for patients for whom there is no conventional surgical option. This complex surgical intervention requires the combined skills of both peritoneal malignancy and transplant teams.
报告我们在无法进一步进行细胞减灭术(CRS)的复发性假性黏液瘤(PMP)患者中,联合根治性手术切除和肠移植的经验。
CRS 和术中加热腹腔化疗是许多 PMP 患者的有效治疗方法。在广泛小肠受累或无法切除的复发病例中,疾病进展导致小肠梗阻、营养衰竭和瘘管形成,导致腹壁衰竭。
在 2013 年至 2022 年间,我们中心对出现营养衰竭且不适合进一步 CRS 的 PMP 患者进行了根治性减瘤和肠移植。
15 例患者接受了受累腹腔器官的根治性切除术,并根据个体情况进行了肠移植。8 例患者进行了单纯小肠移植,7 例患者进行了改良多器官移植。此外,在 7 例腹壁肿瘤广泛受累的患者中,进行了全层血管化腹壁移植。15 例患者中有 2 例在 90 天内死于与手术相关的并发症。患者的 1 年和 5 年存活率分别为 79%和 55%。大多数患者在移植后生活质量有显著改善。随访超过 6 个月的患者中,有 91%发现疾病进展/复发。
与传统手术方法相比,肠/多器官移植使 PMP 的管理能够更加彻底,适用于没有传统手术选择的患者。这种复杂的手术干预需要腹膜恶性肿瘤和移植团队的综合技能。